The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Crossref DOI link: https://doi.org/10.1038/bcj.2017.69
Published Online: 2017-07-28
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Besse, L
Kraus, M
Besse, A
Bader, J
Silzle, T
Mehrling, T
Driessen, C
Text and Data Mining valid from 2017-07-28
Version of Record valid from 2017-07-28
Article History
First Online: 28 July 2017
Competing interests
: The authors declare no conflict of interest.